Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Robert S DiPaola
Adjuvant Sunitinib or Sorafenib for High-Risk, Non-Metastatic Renal-Cell Carcinoma (ECOG-ACRIN E2805): A Double-Blind, Placebo-Controlled, Randomised, Phase 3 Trial
The Lancet
Medicine
Related publications
Pazopanib for Metastatic Soft-Tissue Sarcoma (PALETTE): A Randomised, Double-Blind, Placebo-Controlled Phase 3 Trial
The Lancet
Medicine
Phase III Trial of Adjuvant Sunitinib in Patients With High-Risk Renal Cell Carcinoma: Exploratory Pharmacogenomic Analysis
Clinical Cancer Research
Cancer Research
Oncology
Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma After Nephrectomy
New England Journal of Medicine
Medicine
Docetaxel and Dasatinib or Placebo in Men With Metastatic Castration-Resistant Prostate Cancer (READY): A Randomised, Double-Blind Phase 3 Trial
The Lancet Oncology
Oncology
Phase I Trial of Sunitinib and Temsirolimus in Metastatic Renal Cell Carcinoma
Clinical Genitourinary Cancer
Oncology
Urology
Aspirin for Prophylaxis Against Headache at High Altitudes: Randomised, Double Blind, Placebo Controlled Trial
BMJ
A Randomised, Double-Blind, Placebo-Controlled Multi-Centre Phase III Trial of XELIRI/FOLFIRI Plus Simvastatin for Patients With Metastatic Colorectal Cancer
British Journal of Cancer
Cancer Research
Oncology
Olaparib Combined With Abiraterone in Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial
The Lancet Oncology
Oncology
Adjuvant Imatinib Mesylate After Resection of Localised, Primary Gastrointestinal Stromal Tumour: A Randomised, Double-Blind, Placebo-Controlled Trial
The Lancet
Medicine
